Search
Hydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. … [T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain.
Mixtures: Vicodin ES, Vicodin ESProducts: Zohydro ER, Vantrela ERPemetrexed
go.drugbank.com/drugs/DB00642ApprovedInvestigationalIts use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907] … It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative
Products: PEMETREXED EG, Pemetrexed Actavis 100 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungNimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnDue to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
Products: MESULID SUSPENSION PARA ADMINISTRACIÓN EN GOTAS, NIMESULIDE EGTiopronin
go.drugbank.com/drugs/DB06823ApprovedTiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. … It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization.
Categories: N-substituted GlycinesProducts: Thiola ECOxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalIt is often used as first-line therapy for OAB.[A185990] … efficacy since initial FDA approval in 1975.
Products: OXIBUTININA EG, Pat-oxybutynin Chloride ERHomeobox protein engrailed-2
go.drugbank.com/bio_entities/BE0004484TargetHumansSynonyms: Hu-En-2, Homeobox protein en-2Phendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Products: Fendique ER, Phendimetrazine Tartrate ERLevosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan is under investigation in clinical trial NCT00527059 (Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure). … Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels.
Categories: Compounds used in a research, industrial, or household settingProducts: LEVOSIMENDAN EG, Levosimendan Carinopharm 12,5 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus.
Synonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaCategories: Drugs Used in DiabetesAmsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. … It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Categories: Compounds used in a research, industrial, or household settingProducts: Amlyo 75 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Amsidyl 75 mg/1,5 ml Konzentrat und Lösungsmittel für ein Konzentrat zur Herstellung einer Infusionslösung